Friday, 23 June 2017

Merck’s Keytruda prolong life in lung cancer study

According to report, Merck & Co's
approved Keytruda lung cancer
treatment is said to provided superior
overall survival to chemotherapy.

This is confirmed
in a late-stage study of patients
with advanced disease whose
tumors produce a protein called
PD-L1 associated with increased
risk of the disease.

No comments:

Post a Comment

Mental health could cost the global economy up to $16 trillion between 2010 and 2030

According to an expert, mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 tr...